ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,827.04
      -1.54%
      US Tech 100
      20,287.60
      0.00%
      Dow Jones
      41,938.45
      -1.63%
      Brent Oil
      80.505
      -0.14%
      Bitcoin
      93,377.50
      -1.17%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. UK
      5. LSE

      6. Molecular Partners Ag (0QXX) Quote

      Molecular Partners Ag

      Molecular Partners Ag (0QXX)

      LSE
      25.20
      0.00
      ( 0.00% )
      Updated: 19:00:00
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      25.20
      Bid
      0.00
      Ask
      0.00
      Volume
      0.00
      0.00 Day's Range 0.00
      25.20 52 Week Range 25.20
      Market Cap
      916.121M
      Previous Close
      25.20
      Open
      -
      Last Trade
      (O)
      Last Trade Time
      -
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      526
      Shares Outstanding
      36,354,000
      Dividend Yield
      -
      PE Ratio
      -14.78
      Earnings Per Share (EPS)
      -1.71
      Revenue
      7.04M
      Net Profit
      -61.98M

      About Molecular Partners Ag

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.molecularpartners.com
      Headquarters
      Schlieren, Che
      Founded
      -
      Molecular Partners Ag is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QXX. The last closing price for Molecular Partners was CHF25.20. Over the last year, Molecular Partners shares have traded in a share price range of CHF 25.20 to CHF 25.20.

      Molecular Partners currently has 36,354,000 shares outstanding. The market capitalization of Molecular Partners is CHF916.12 million. Molecular Partners has a price to earnings ratio (PE ratio) of -14.78.

      Ask ADVFN Intelligence (AI)

      0QXX Latest News

      More News

      Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

      Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference Radio-DARPin MP0712 against DLL3, in...

      14 hours ago
      UK Regulatory

      Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

      Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer New agreement enables both companies to fuel a broad and innovative pipeline of...

      14 hours ago
      UK Regulatory

      Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

      Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE...

      December 17 2024
      UK Regulatory

      Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

      Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 MP0533 phase 1/2a dose escalation study...

      December 08 2024
      UK Regulatory

      Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

      Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 Preclinical proof-of-concept data supports the...

      November 07 2024
      UK Regulatory

      Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

      Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall...

      November 05 2024
      UK Regulatory

      Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

      Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going Radio-DARPin Therapy...

      October 31 2024
      UK Regulatory

      Molecular Partners Announces Pricing of $20 Million Underwritten Offering

      Molecular Partners Announces Pricing of $20 Million Underwritten Offering ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art...

      October 25 2024
      UK Regulatory

      Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

      Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics Under the revised agreement, both companies will co-develop four Radio-DARPin programs;...

      October 22 2024
      UK Regulatory

      Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

      Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 Dose-dependent efficacy observed with...

      October 22 2024
      UK Regulatory
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10025.225.225.224025.2DE
      40025.225.225.227525.2DE
      120025.225.225.252625.2DE
      260025.225.225.235525.2DE
      520025.225.225.237925.2DE
      1560025.225.225.2632125.2DE
      2600025.225.225.2518225.2DE

      0QXX - Frequently Asked Questions (FAQ)

      What is the current Molecular Partners share price?
      The current share price of Molecular Partners is CHF 25.20
      How many Molecular Partners shares are in issue?
      Molecular Partners has 36,354,000 shares in issue
      What is the market cap of Molecular Partners?
      The market capitalisation of Molecular Partners is CHF 916.12M
      What is the 1 year trading range for Molecular Partners share price?
      Molecular Partners has traded in the range of CHF 25.20 to CHF 25.20 during the past year
      What is the PE ratio of Molecular Partners?
      The price to earnings ratio of Molecular Partners is -14.78
      What is the cash to sales ratio of Molecular Partners?
      The cash to sales ratio of Molecular Partners is 130.17
      What is the reporting currency for Molecular Partners?
      Molecular Partners reports financial results in CHF
      What is the latest annual turnover for Molecular Partners?
      The latest annual turnover of Molecular Partners is CHF 7.04M
      What is the latest annual profit for Molecular Partners?
      The latest annual profit of Molecular Partners is CHF -61.98M
      What is the registered address of Molecular Partners?
      The registered address for Molecular Partners is WAGISTRASSE 14, SCHLIEREN, 8952
      What is the Molecular Partners website address?
      The website address for Molecular Partners is www.molecularpartners.com
      Which industry sector does Molecular Partners operate in?
      Molecular Partners operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      0A2IH World Group Ltd
      $ 0.00
      (0.00%)
      		0
      0A2DCrh Plc
      $ 0.00
      (0.00%)
      		0
      0A2BBanco Bilbao Vizcaya Argentaria Sa
      $ 0.00
      (0.00%)
      		0
      0A22Anheuser Busch Inbev Nv
      $ 0.00
      (0.00%)
      		0
      0A1UUber Technologies Inc
      $ 66.00
      (0.00%)
      		1.65k
      0A2IH World Group Ltd
      $ 0.00
      (0.00%)
      		0
      0A2DCrh Plc
      $ 0.00
      (0.00%)
      		0
      0A2BBanco Bilbao Vizcaya Argentaria Sa
      $ 0.00
      (0.00%)
      		0
      0A22Anheuser Busch Inbev Nv
      $ 0.00
      (0.00%)
      		0
      0A1UUber Technologies Inc
      $ 66.00
      (0.00%)
      		1.65k
      0R0XTesla Inc
      $ 388.20
      (0.00%)
      		4.74k
      0JOQJd.com Inc
      $ 72.00
      (0.00%)
      		3.03k
      0HCIAlibaba Group Holding Ltd
      $ 81.10
      (0.00%)
      		2.3k
      0R1OAmazon.com Inc
      $ 217.50
      (0.00%)
      		1.67k
      0P4FFord Motor Co
      $ 9.665
      (0.00%)
      		1.67k

      Discussion

      View Full Feed
      DiamondHealer95 DiamondHealer95 2 minutes ago
      I mean Kim said once they hit 1.5 metric tons they're open for business and they're about halfway there so..... You're a genius! Congrats on the business. I also run one with 100% positive feedback over 22 years 🤪
      KBLB
      DiamondHealer95 DiamondHealer95 5 minutes ago
      We've invested similarly
      KBLB
      sunspotter sunspotter 16 minutes ago
      Glenn Miller’s still missing, and Emil Malak and Rich Inza are still crooks.
      VPLM
      Flobewan Flobewan 27 minutes ago
      Marc loved your ides
      tinojax tinojax 28 minutes ago
      I usually enjoy a beer with my pizza...........I would like to know what's in the Kool Aid........
      PLUG
      mrfence mrfence 31 minutes ago
      Here we are on the cusp of the Monsta $FMCC~ $FNMA~ Gains we've all been waiting for doin da Heebie Jeebie Dance, 😃😄😁😆😅😂!
      [yt]MUB3ZR4F8vw?si=Z3oB5zc_RHMtCGEY[/yt]
      FMCC FNMA
      IVRT IVRT 47 minutes ago
      In my opinion, there will likely be significant pressure on the share price leading up to the conference call. A sell-off could occur the day before, with the stock potentially bottoming out by the end of the investor call. I could be wrong, but I've seen similar patterns many times over the past 25
      BMXI
      DewDiligence DewDiligence 47 minutes ago
      GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

      https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

      ENTA
      DewDiligence DewDiligence 48 minutes ago
      GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

      https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

      Guido2 Guido2 49 minutes ago
      This is DUE DILIGENCE! Thank you Free Fannie.

      https://x.com/freefannie/status/1878655047715991552?s=46&t=2Y42DPZFgRdwTBHj5W8jMQ
      FNMA
      StockItOut StockItOut 55 minutes ago
      That Xeriant PR excellently written with bullshit:

      ""After successfully completing 75% of the demanding NFPA 286 test," meaning = "after failing the NFPA 286 test by missing 25% of the approval target testing requirement,"

      "the Company used the data to make several key
      XERI
      gitreal gitreal 58 minutes ago
      You were actually partially right....BMXI has filed some SEC documents, some necessary (Form 1-A), some unnecessary (Form 4). And they do summarize a lot of the stuff that I think are fabrications....their production, mining operations, etc. Time will tell, but I think a lot of it (and probably
      BMXI
      RichieBoy RichieBoy 1 hour ago
      Jim wrote a blurb about seeking more US business.

      Help you out any? 🤨
      AFFU
      DesktopDR DesktopDR 1 hour ago
      Any news or updates?
      VPLM
      Tahoe2468 Tahoe2468 1 hour ago
      .0915 by Thursday....... 
      KRTL
      skitahoe skitahoe 1 hour ago
      Remember GBM was redefined during the trial, thus some who were treated then had other forms of brain cancer. I believe the least we'll see in our label is brain cancer. Certainly GBM may be the deadliest of them, but treatment should work in all of them.

      According to Google, GBM ha
      NWBO
      fuagf fuagf 1 hour ago
      You are right about the crafty, evil, smart. Authoritarian methods have been in full view
      in capturing America. While we work to do the right things they plot to capture the lot.
      facts_matter14 facts_matter14 1 hour ago
      If there weren’t suckers born every minute, there wouldn’t be POSRMX bag holders down as much as 99%, and there sure as hell wouldn’t be anybody believing there is a pipeline of products.






      .
      SRMX
      StockItOut StockItOut 1 hour ago
      Your "closer" keeps getting extended. Then again extended. Then again extended. -- Consider that end. Now expired, horizon end now reached, and the view clarifies and we see it to be your desperation from years ago ongoing still, to pump this at any expense, where you attempt to instill FOMO to hold
      XERI
      fuagf fuagf 1 hour ago
      He would smother any question with words.
      Shawonsarker84 Shawonsarker84 1 hour ago
      $HMBL Sorry HMBL investors. XTIA now broke the record 2.7B share volume traded before the reverse split.



      https://x.com/shawonsarker84/status/1878696680088019193?t=rZlhkn2Jos4vWKxxQgXGfA&s=19
      HMBL XTIA
      chen1992 chen1992 1 hour ago
      https://www.energy.senate.gov/hearings/2025/1/hearing-to-consider-the-nomination-of-mr-chris-wright-to-be-secretary-of-energy

      https://www.commerce.senate.gov/2025/1/full-committee-nomination-hearing_2#:~:text=U.S.%20Senator%20Ted%20Cruz%20(R,Wednesday%2C%20January%2015%2C%20
      TGLO
      FNM500K FNM500K 1 hour ago
      Oh noooooo.....
      FNMA
      StockItOut StockItOut 1 hour ago
      OTC filings and attorney statements. my error.

      Point that it is on you to prove your claim, that:
      "There's no contract employees. There's no production shafts."

      Likewise for the company to do so, as we wait for an audit, apparently indefinitely.

      I
      BMXI

      Your Recent History

      LSE
      0QXX
      Molecular Partners
      LSE
      0K05
      Medifast
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads